ClinicalTrials.gg
WithdrawnNCT02495129Updated Apr 20, 2017

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

A Phase 1/2 interventional study of VAY736 lower dose and VAY736 higher dose in Primary Sjögren's Syndrome, sponsored by Novartis Pharmaceuticals. Withdrawn. Per ClinicalTrials.gov, last updated 2017-04-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.

Enrollment
14th of 14
0 · median 240
Started
2015
the only one that year
Phase 1/2
Only one
of the 15
Registered
2nd of 15
by date

Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 1/2, and was the 2nd registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sjogren's Syndrome by Novartis, or all of them as a file.
02

Study summary

This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method is a valid method to assess B cells in salivary glands of pSS patients. In Part 1 and Part 2 no IMP will be applied to the subjects. In Part 3, pSS patients (n=12) will receive the IMP, VAY736. Posted information will be focused on Part 3.

The overarching purpose of this study is to test a new drug (VAY736) for the treatment of pSS. In pSS, the salivary glands (the glands that produce saliva) and other organs are affected by inflammation. A certain type of white blood cells called B cells prominently infiltrate the salivary glands in pSS, whereas they are not present in healthy salivary glands. Scientific evidence suggests that B cells may be involved in the disease process in pSS and that eliminating B cells may benefit patients with pSS. This study will test a new imaging method and a new treatment for pSS. Both the imaging method and the treatment are specific for B cells.

03

Conditions studied

  • Primary Sjögren's Syndrome

Browse trials for

Keywords

  • Primary Sjögren's syndrome
  • Sicca syndrome
  • Salivary glands
  • Positron Emission Tomography
  • B cell depletion
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part 1 and 3:

Inclusion Criteria:

  • Fullfilled consensus criteria for primary Sjögren's syndrome
  • Patients must have elevated serum levels for some Sögren Syndorme specific parameters such as antinuclear antibodies (ANA), rheumatoid factor (RF) etc.

Exclusion Criteria:

  • Patients that are suffering from Secondary Sjögren's syndrome.
  • Patients previously treated with monoclonal antibody treatments such as rituximab, infliximab, adalimumab, etc.

Part 2

Inclusion criteria:

  • healthy male and female people 18-75 years of age

Exclusion criteria:

  • Use of other drugs at the time of enrollment
  • Exposure to a sizeable degree of radiation (≥ 5 mSv) in an investigational research study in the past year prior to this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    VAY736 lower dose

    12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)

    Drug: VAY736 lower dose

  • Experimental
    VA736 higher dose

    12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)

    Drug: VAY736 higher dose

Interventions

  • Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736

  • Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736

06

What researchers measure

Primary outcomes

  1. Part 1: To determine the feasibility of measuring major salivary gland infiltrating B cells in pSS patients using [Zr- 89]rituximab PET/CT imaging

    Part 1: PET/CT imaging of pSS major salivary gland 3, 6 and 9 days after i.v. injection with \[Zr- 89\]rituximab

    Time frame: Part 1: 4 weeks

  2. Part 2: To define the normal range of PET/CT imaging values for major salivary gland tissue, cervical lymph nodes and spleen in healthy volunteers with [Zr-89]-rituximab

    Part 2: PET/CT imaging of healthy volunteers' major salivary gland, cervical lymph nodes and spleen on optimal time point after i.v. injection with \[Zr-89\]-rituximab (e.g. 3 days after injection)

    Time frame: Part 2: 4 weeks

  3. Part 3: To compare the effect of two different VAY736 s.c. dose regimes on salivary gland-infiltrating B cells in pSS patients, using [Zr-89]-rituximab PET/CT imaging

    Part 3: PET/CT imaging of pSS tissues on optimal time point after i.v. injection with \[Zr-89\]-rituximab, at baseline and 12 weeks after the start of VAY736 treatment

    Time frame: Part 3: 12 weeks

Secondary outcomes

  1. Safety of multiple s.c. dosing of VAY736 in pSS patients as measured by safety assessments

    AEs, vital signs, ECGs, safety laboratory parameters (Hematology, Biochmistry, Urinalysis)

    Time frame: 12 weeks

  2. To asses the pharmacokinetiks of VAY736 in pSS patients

    Multiple s.c. dose VAY736 PK parameter - Area under the curve (AUC)

    Time frame: 12 weeks

  3. To assess the pharmacokinetiks of VAY736 in pSS patients

    Multiple s.c. dose VAY736 PK parameter - Trough concentrations after multiple dose

    Time frame: 12 weeks

  4. Assess the pharmacodynamic effect of VAY736 on circulating CD19+ B-cells in pSS

    Multiple s.c. dose VAY736 PD parameter - depletion of B cells

    Time frame: 12 weeks

  5. Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS

    Assess size of spleen and cervical lyph nodes by PET/CT imaging and ultrasound-aided size measurements

    Time frame: 12 weeks

  6. Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS

    Assess salivary glands size and echostructure by ultrasound

    Time frame: 12 weeks

  7. Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS

    Assess salivary gland function (quantitative) by salivary flow (stimulated and unstimulated)

    Time frame: 12 weeks

  8. Asses effect of two different VAY736 dose levels on target tissue structure and function in pSS

    Assess lacrimal gland function by Schirmer's test

    Time frame: 12 weeks

  9. To evaluate the effect of two different VAY736 dose levels (s.c. q4w) on pSS disease activity

    Assess the change in the EULAR Sjögren'sSyndrome Disease Activity Index (ESSDAI).

    Time frame: 12 weeks

  10. To evaluate the effect of on self-reported outcomes in pSS patients

    Multidimensional Fatigue Inventory (MFI-20); the short form 36 health Survey (SF-36); EULAR Sjögren's Syndorm Patient Reported Intensity (ESSPRI)

    Time frame: 12 weeks

  11. To evaluate the change in the physician global assessment of patients's overall disease activity

    Physician's visual anaglog scale (VAS)

    Time frame: 12 weeks

  12. To evaluate the change in the patients global assessment of their disease activity

    Patient's visual analogue scale (VAS)

    Time frame: 12 weeks

  13. To assess the immunogenicity of VAY736

    Anti-VAY736 antibodies

    Time frame: 12 weeks

  14. To assess the immunogenicity of a micodose of rituximab

    Anti-rituximab antibodies

    Time frame: 25 weeks

  15. To asses the pharmacokinetiks of VAY736 in pSS patients

    Multiple s.c. dose VAY736 PK parameter - Cmax

    Time frame: 12 weeks

  16. To asses the pharmacokinetiks of VAY736 in pSS patients

    Multiple s.c. dose VAY736 PK parameter - tmax

    Time frame: 12 weeks

  17. To asses the pharmacokinetiks of VAY736 in pSS patients

    Multiple s.c. dose VAY736 PK parameter - half live (t1/2)

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Sep 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2015
First posted
Jul 13, 2015
Start
Dec 2015
Primary completionEst.
Sep 2017
CompletionEst.
Sep 2017
Last update
Apr 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02495129
Responsible party
Sponsor
First posted
Jul 13, 2015
Start date
Dec 2015
Primary completion
Sep 2017 (estimated)
Completion
Sep 2017 (estimated)
Last update
Apr 20, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion